Hodgkin’s lymphoma after 2-month infliximab therapy: case report

Saeidi S., Ahmadzadeh A., Rajaei E., RAHIM F., Jazayeri S. N., Shahjahani M., ...Daha Fazla

Comparative Clinical Pathology, cilt.24, sa.4, ss.911-914, 2015 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s00580-014-2007-6
  • Dergi Adı: Comparative Clinical Pathology
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.911-914
  • Anahtar Kelimeler: Ankylosing spondylitis, Hodgkin’s lymphoma, Infliximab, Rheumatoid arthritis, TNF-α
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the axial skeleton. Joint pain and stiffness as well as reduced spinal mobility are among the clinical symptoms of this disease. AS mostly affects younger males. TNF blocker drugs like infliximab are among the best treatments for AS, relieving many symptoms of the disease by neutralizing the effect of TNF. However, the use of these drugs may increase the risk of malignancies. In this research, a 23-year-old male with a history of AS was investigated, who was afflicted with Hodgkin’s lymphoma as a rare complication following infliximab administration.